Published in Br J Clin Pharmacol on October 01, 1990
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol (2004) 1.02
The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet (1995) 0.79
The outcomes of patients with severe hyperbilirubinemia following living donor liver transplantation. Dig Dis Sci (2013) 0.78
Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol (2017) 0.75
THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN. J Clin Invest (1945) 20.72
The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci (1961) 6.71
Estimation of hepatic blood flow with indocyanine green. J Clin Invest (1962) 2.30
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
The use of indocyanine green for the evaluation of hepatic function and blood flow in man. Am J Dig Dis (1960) 1.64
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol (1979) 1.45
Clearance and non-invasive determination of the hepatic extraction of indocyanine green in baboons and man. Clin Sci (Lond) (1983) 1.40
Effect of age on liver function with particular reference to bromsulphalein excretion. Gut (1965) 1.24
Plasma level of chlormethiazole and two metabolites after oral administration to young and aged human subjects. Eur J Clin Pharmacol (1977) 0.97
Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol (1988) 0.96
Age and the pharmacokinetics of morphine. Age Ageing (1989) 0.94
The estimation of hepatic blood flow with indocyanine green: comparison between the continuous infusion and single injection methods. Am J Gastroenterol (1982) 0.90
Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. Acta Med Scand Suppl (1984) 0.80
Bioavailability of labetalol increases with age. Br J Clin Pharmacol (1982) 0.78
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
North of England evidence based guidelines development project: methods of guideline development. BMJ (1996) 5.12
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Natural history of early primary biliary cirrhosis. Lancet (1996) 3.24
Reduction in incidence of severe paracetamol poisoning. Lancet (2000) 3.06
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
Standardized functional assessment scales for elderly patients. Age Ageing (1993) 2.77
QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet (1993) 2.73
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet (1995) 2.64
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project. Qual Health Care (1996) 2.49
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
Blindness in the Luapula valley. Cent Afr J Med (1967) 2.32
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
Long-term outcome for patients and carers following hospital admission for stroke. Age Ageing (1991) 2.27
The discharge of elderly patients from an accident and emergency department: functional changes and risk of readmission. Age Ageing (1990) 2.17
Who should have a PEG? Age Ageing (1993) 2.12
Doctors and the drug makers. Lancet (1984) 2.09
Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol (1998) 2.08
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet (1999) 2.06
Extending the role of the community pharmacist. BMJ (1991) 2.05
Adverse drug reactions in elderly patients. Br J Clin Pharmacol (2004) 2.02
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
The prevalence of stroke and associated disability. J Public Health Med (1999) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Hepatic steatosis: innocent bystander or guilty party? Hepatology (1998) 1.94
Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet (1988) 1.90
Is the SF-36 suitable for assessing health status of older stroke patients? Age Ageing (1998) 1.89
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Clinical staging in Reye syndrome. Am J Dis Child (1974) 1.84
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Validation of a population screening questionnaire to assess prevalence of stroke. Stroke (1995) 1.78
Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet (1983) 1.78
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Delays to thrombolysis in the treatment of myocardial infarction. J R Coll Physicians Lond (1993) 1.75
Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA (1998) 1.73
Psoriasis and cancer. Br Med J (1979) 1.71
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A (1988) 1.62
Predicting patients' warfarin requirements. Lancet (1977) 1.61
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 1.59
Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology (1999) 1.58
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet (1978) 1.49
A survey of phlebotomy among persons with hemochromatosis. Transfusion (1999) 1.49
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med (1990) 1.43
HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol Dis (2000) 1.42
Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin (2000) 1.42
A study of nutritional deficits of long-stay geriatric patients. Age Ageing (1993) 1.42
Comparison of Nottingham Health Profile (NHP) scores with exercise duration and measures of ischaemia during treadmill exercise testing in patients with coronary artery disease. Eur Heart J (1995) 1.41
Use of vibrational angioplasty for the treatment of chronic total coronary occlusions: preliminary results. Catheter Cardiovasc Interv (1999) 1.41
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. Br Heart J (1995) 1.40
Effects of physical activity and age on mitochondrial function. QJM (1996) 1.39
Spontaneous periodic hypothermia: diencephalic epilepsy. Br Med J (1973) 1.39
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med (1986) 1.39
Respiratory failure after chest injury: the development of effective treatment. Ann R Coll Surg Engl (1982) 1.39
Body protein metabolism and plasma amino acids in cirrhosis of the liver. The effect of varying the branched chain amino acid content of intravenous amino acid solutions. Clin Nutr (1984) 1.39
A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med (1999) 1.39
ECG for physicians: Brugada syndrome. Resuscitation (2006) 1.39
Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ (1993) 1.38
Marfan's syndrome and coarctation. Coincidence or association? A case report. Angiology (1990) 1.38
Vibrational angioplasty and hydrophilic guidewires in the treatment of chronic total coronary occlusions. J Endovasc Ther (2000) 1.38
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed) (1985) 1.36
Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol (1999) 1.36
Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed) (1981) 1.35
Pacemaker-induced superior vena cava syndrome: report of four cases and review of the literature. Pacing Clin Electrophysiol (1989) 1.33
Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology (1987) 1.32
Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury (1998) 1.32
A method for obtaining saliva samples from infants and young children. Br J Clin Pharmacol (1978) 1.32
Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (1999) 1.31
Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J Antimicrob Chemother (2000) 1.29
Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med (1998) 1.28